Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp > Entertainment at its finest!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(18325)
•••
Comment by Joe455on Apr 02, 2022 8:16pm
247 Views
Post# 34570616

RE:RE:RE:Entertainment at its finest!

RE:RE:RE:Entertainment at its finest!
Pandora wrote:
navajojoe wrote: I wouldn't doubt that every single shareholder who has been holding this mutt, waiting for the big revenue numbers from the R&F deal, have realised that it has been a complete waste of valuable investment capital. Some have made good money selling on every bit of news or third-party pump, buying back on the inevitable collapse when nothing real happens. I have done a little of that myself, but always thought that maybe "this time will be different". Well, no more. I will be selling if they ever do put out a news release about that "global pharma" deal, because if history repeats, it will be just another disappointment. And I know I won't be alone. So it will be a tough slog higher, unless the deal is actually a company-maker, and the profit details are clearly presented.

I am open to be being pleasantly surprised, but prepared for the last days of being a SBM shareholder.


What's that saying they use at this point?      Hear! Hear!

Get the Kardashians on board and the money will flow!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities